Great news...
"MGH will perform additional analysis" -
What additional analysis it is referring to which apps algorithm and data analytics do not include ?
Why not add this additional analysis functionality in-built into the apps and use in clinical trials to ease FDA approvals ?
Would this tie-up delay or expedite fda approvals?
Ann: ResApp Announces Expanded Research Collaboration with MGH, page-12
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #